News

Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is whether this momentum can last.

AstraZeneca (NASDAQ: AZN) and Bristol Myers Squibb (NYSE: BMY) are the two directly affected public companies; AZN bears the most immediate price risk given it absorbed a roughly 9% single-day selloff on Monday when the merger speculation first emerged, while BMY shareholders were widely viewed as the primary beneficiaries of any combination.

Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.

Strong revenue growth driven by Eliquis and key growth assets, offset by Opdivo decline and delayed readouts for Milvexian and Cobenfy.

Bristol Myers Squibb (NYSE:BMY) reported second-quarter results that comfortably exceeded Wall Street expectations, driven by continued strength across its growth portfolio. The pharmaceutical company also raised its full-year 2026 financial outlook, sending its shares more than 1% higher in premarket trading on Thursday.

Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates

Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.

Bristol Myers Squibb said on Monday it is buying the latest-generation computing system from chip company Nvidia ‌to support its use of artificial intelligence across its drug discovery and development ‌operations. The drugmaker said it will be the first life sciences company to buy an Nvidia DGX SuperPOD ​based on its Vera Rubin systems. The chipmaker unveiled its Vera Rubin architecture earlier this year as the successor to its current generation of AI computing systems.

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

(Bloomberg) -- At the Hirslanden clinic overlooking Switzerland’s picturesque Lake Lucerne, prostate cancer patient Jörg Pegelow lies on a reclining chair as a doctor wearing two sets of gloves — one made with lead — injects a saline solution laced with a radioactive drug into a vein in his arm.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapOracle Cut 21,000 Jobs in 12 Months, Says AI Replaced

Investing.com -- Kardigan Inc. shares rose iver 27% roughly one hour into its Nasdaq debut on Thursday, after the heart-health focused biotech raised $400 million in an initial public offering.

BioArctic AB (BRCTF) reports robust financial performance and advances in Alzheimer's treatment, while navigating market access hurdles and rising operational costs.